Travere Therapeutics (NASDAQ: TVTX) director plans 5,000-share sale tied to stock options

Rhea-AI Filing Summary

Travere Therapeutics, Inc. (TVTX) received a notice that director Gary Lyons plans to sell company common stock under Rule 144. The planned transaction involves 5,000 shares of common stock, with a stated aggregate market value of $317,650.00, through Morgan Stanley Smith Barney on or about 08/18/2026. The shares are to be sold in connection with the exercise of stock options for cash. The notice also lists a prior 10b5-1 sale of 5,000 shares on 08/17/2026 for total proceeds of $315,985.50.

Key Figures

Planned shares to be sold: 5,000 shares Aggregate market value of planned sale: $317,650.00 Shares sold in prior 3 months: 5,000 shares +2 more

5 metrics

Planned shares to be sold 5,000 shares Common stock to be sold by Gary Lyons on or about 08/18/2026

Aggregate market value of planned sale $317,650.00 Estimated value of 5,000 TVTX shares for planned Rule 144 sale

Shares sold in prior 3 months 5,000 shares 10b5-1 sale on 08/17/2026

Proceeds from prior 10b5-1 sale $315,985.50 Total for 5,000 common shares sold on 08/17/2026

Rule 144 notice date 08/18/2026 Date listed for proposed sale and signature

Key Terms

Rule 144, 10b5-1, Exercise of Stock Options

3 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

10b5-1 regulatory

"10b5-1 Sales for GARY LYONS 3611 Valley Centre Drive"

A 10b5-1 plan is a pre-set schedule that lets company insiders buy or sell shares according to written instructions made when they do not possess material, nonpublic information. Think of it as a timed automatic payment for stock trades: it helps insiders avoid accusations of trading on secret information and gives outside investors a clearer signal about whether sales are routine or potentially informative about the company’s prospects.

Exercise of Stock Options financial

"Common | 08/18/2026 | Exercise of Stock Options | Issuer"

FAQ

What insider sale is disclosed for Travere Therapeutics (TVTX) in this Form 144?

The filing discloses that director Gary Lyons plans to sell 5,000 shares of Travere Therapeutics common stock. The planned sale, valued at an aggregate $317,650.00, is associated with the exercise of stock options on or about 08/18/2026.

What is the planned transaction date and value for the TVTX shares to be sold?

The planned sale date is 08/18/2026 for 5,000 shares of Travere Therapeutics common stock. The notice lists an aggregate market value of $317,650.00 for these shares, to be sold for cash through Morgan Stanley Smith Barney.

How many Travere Therapeutics (TVTX) shares did Gary Lyons sell in the past 3 months?

The document reports a prior 10b5-1 transaction in the past three months involving 5,000 shares of Travere Therapeutics common stock. That sale occurred on 08/17/2026 and generated total proceeds of $315,985.50.

What is the basis for the planned TVTX stock sale under this notice?

The planned sale of 5,000 shares of Travere Therapeutics common stock is tied to the exercise of stock options. The securities to be sold section specifies “Exercise of Stock Options” as the nature of acquisition, with the sale for cash on 08/18/2026.

Which broker is listed for the planned Travere Therapeutics (TVTX) share sale?

The planned sale of 5,000 TVTX shares is routed through Morgan Stanley Smith Barney LLC Executive Financial Services. The broker’s address is listed as 1 New York Plaza, 8th Floor, New York, NY 10004, with the shares trading on NASDAQ.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/18/2026 - 04:25 PM Accepted by SEC EDGAR 08/18/2026 - 04:24 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001123343
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	TRAVERE THERAPEUTICS, INC.
SEC File Number	001-36257
Address of Issuer	3611 Valley Centre Drive, Suite 300 San Diego CALIFORNIA 92130
Phone	8889697879
Name of Person for Whose Account the Securities are To Be Sold	GARY LYONS
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	5000	317650.00	94261082	08/18/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/18/2026	Exercise of Stock Options	Issuer			5000	08/18/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
10b5-1 Sales for GARY LYONS 3611 Valley Centre Drive, Suite 300 San Diego CA 92130	Common	08/17/2026	5000	315985.50

144: Remarks and Signature

Remarks
Date of Notice	08/18/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	05/18/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Gary Lyons
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)